Discontinuation Syndrome Associated with Paroxetine in Depressed Patients: A Retrospective Analysis of Factors Involved in the Occurrence of the Syndrome
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective To examine the factors that contribute to the occurrence of the discontinuation syndrome in patients who have received paroxetine to treat depression. Method The clinical records of individuals from the outpatient units of two centres in the western area of Japan who had had a single episode of major depressive disorder (MDD) and had completed monotherapy with paroxetine in the previous 5 years were retrospectively reviewed. All patients had been diagnosed with MDD according to the DSM-IV criteria. The patients were divided into two groups, according to whether or not they had experienced the discontinuation syndrome when paroxetine was stopped. The syndrome was diagnosed according to standard criteria for the SSRI discontinuation syndrome. The two groups were compared for sex, age, maintenance dosage of paroxetine, duration of treatment with paroxetine, presence of adverse reactions in the early phase of treatment with paroxetine, and method of paroxetine withdrawal (abrupt or tapered). Results Of the 385 patients included in the review, 41 patients experienced the discontinuation syndrome. The occurrence of the discontinuation syndrome did not correlate with sex, maintenance dosage of paroxetine or duration of treatment with the drug. However, there was a relationship between the method of drug withdrawal and the occurrence of the discontinuation syndrome, with the syndrome occurring significantly more frequently in those patients in whom paroxetine was abruptly d…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The retrospective cohort study found that withdrawal syndrome occurred significantly less frequently in patients who discontinued gradually compared with patients who discontinued abruptly, and most patients could discontinue paroxetine with a taper of 5 mg every two or four weeks (Himei 2006).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Himei 2006
In the citing paper
“Slower tapering will provide more time for these neuroadaptations and are likely to diminish withdrawal severity 33,44,47 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [33]
In the citing paper
“It has generally been concluded from these studies that longer tapering regimes are required 3,33 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [33]
In the citing paper
“The study showed that placebo substitution, but not continued active medication, was associated with statistically significant increases in total numbers of solicited adverse events for patients treated with paroxetine by the end of the fourth day (p < 0.001).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [37]
In the citing paper
“Studies thus indicate that short-term tapering regimens result in a lower proportion of patients succeeding in discontinuing antidepressants compared with a longer tapering period.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [15]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Green, B. (2003) · Current Medical Research and Opinion · doi:10.1185/030079902125001353 · Cited by 187
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171
Antidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 148
The SSRI discontinuation syndrome
Haddad, P. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200311 · Cited by 126
Newer antidepressants and the discontinuation syndrome.
Haddad, P. M. (1997) · PubMed · Cited by 101
Clinical management of antidepressant discontinuation.
Rosenbaum, J. F., & Zajecka, J. (1997) · PubMed · Cited by 99
Selective serotonin reuptake inhibitor discontinuation syndrome: A review
Tamam, L., & Özpoyraz, N. (2002) · Advances in Therapy · doi:10.1007/bf02850015 · Cited by 77
Research works printed but not linked: 4
- Ables, 2003, Am Fam Physician, 67, 547
- Black, 2000, J Psychiatry Neurosci, 25, 255
- Pyke, 1995, Am J Psychiatry, 152, 149
- Schatzberg, 1996, J Clin Pharmacol, 42, 757, 10.1046/j.1365-2125.1996.00498.x · DOI · Paper page
Cited by
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Bain, K. T., Holmes, H. M., Beers, M. H., Maio, V., Handler, S. M., & Pauker, S. G. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01916.x · Cited by 198
Metadata
- Authors
- Himei, A., & Okamura, T.
- Corresponding author
- Himei, Akio
- Venue
- CNS Drugs
- Published
- 2006
- Volume
- 20
- Issue
- 8
- Pages
- 665-672
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2053188044
- Semantic Scholar
- e5e3783cccb5c5c27417b7ee95acc7a18bf57ba2
- Cited by
- 56
- References
- 18
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 3 · 2012: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- discontinuation syndrome, paroxetine, major depressive disorder, selective serotonin reuptake inhibitors, medication tapering, adverse drug reactions, antidepressant discontinuation, risk factors
- MeSH terms
- Adult, Age Factors, Depression, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Retrospective Studies, Sex Factors, Substance Withdrawal Syndrome, Chi-Square Distribution, Paroxetine, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation Syndrome Associated with Paroxetine in Depressed Patients: A Retrospective Analysis of Factors Involved in the Occurrence of the Syndrome. https://app.cochat.ai/papers/10.2165/00023210-200620080-00005
- The paper
- Himei, A., & Okamura, T. (2006). Discontinuation Syndrome Associated with Paroxetine in Depressed Patients: A Retrospective Analysis of Factors Involved in the Occurrence of the Syndrome. CNS Drugs. https://doi.org/10.2165/00023210-200620080-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.